The global immune checkpoint inhibitors market size was valued at $55.27
billion in 2024. Global revenues are projected to be $63.72 billion in 2025 and
$129.04 billion in 2030 growing at a CAGR of 14.4% from 2025 to 2030 driven
by multiple factors including indication expansion, approvals and adoptions in
earlier lines of therapies, further market penetration, and extension of
duration of therapy.
Key Market Trends & Insights
- Based
on type, the PD-1 segment led the market with the largest revenue
share of 77.5% in 2024.
- Globally,
the top four PD-1/PD-L1 antibody medicines had revenues of approximately $48.47
billion in 2024.
- Based
on indication, Non-Small cell lung cancer (NSCLC) segment led the
market with the largest revenue share of ~35% in 2024.
- United
States dominated the immune checkpoint
inhibitors market for the largest revenue share of 57.70% in 2024.
- Leading
Brand: Keytruda - Despite an increasingly crowded market, Keytruda
has firmly established a dominant position, holding 53.35% ($29,482
million) market share in 2024 making it the undisputed leader among
all checkpoint inhibitors globally.
- Leading
Players (Top 4): Merck & Co., Inc, Bristol-Myers Squibb Company,
Genentech & AstraZeneca
Chapter 1. Market Definition
Chapter 2. Executive Summary
2.1.
Market Outlook
2.2. Competitive
Insights
Chapter 3. Market Dynamics
3.1. Drivers
3.2. Restraints
Chapter 4. Market Analysis
4.1. Porter’s Analysis
4.1.1. Supplier power
4.1.2. Buyer power
4.1.3. Threat of new entrant
4.1.4.
Competitive rivalry
4.2. PESTEL Analysis
Chapter 5. Pricing Analysis
Chapter 6. Pipeline Analysis, By Phase
Chapter 7. Regulatory Framework
Chapter 8. Market Segmentation : Market Estimates and Forecasts
8.1. Global Immune Checkpoint
Inhibitors Market Estimates and Forecasts, by Type, Revenue (USD Million)
8.1.1. PD-1
: Market estimates and forecasts, 2018 to 2030 (USD Million)
8.1.2. PD-L1
: Market estimates and forecasts, 2018 to 2030 (USD Million)
8.1.3. CTLA-4
: Market estimates and forecasts, 2018 to 2030 (USD Million)
8.1.4. LAG -3 : Market estimates and forecasts, 2018 to 2030 (USD Million)
8.2. Global
Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Indication,
Revenue (USD Million)
8.2.1. Lung
Cancer : Market estimates and forecasts, 2018 to 2030 (USD Million)
8.2.2.
Breast Cancer : Market estimates and forecasts, 2018 to 2030 (USD Million)
8.2.3. Bladder
Cancer : Market estimates and forecasts, 2018 to 2030 (USD Million)
8.2.4. Melanoma
: Market estimates and forecasts, 2018 to 2030 (USD Million)
8.2.5. Cervical
Cancer: Market estimates and forecasts, 2018 to 2030 (USD Million)
8.2.6. Colorectal
Cancer: Market estimates and forecasts, 2018 to 2030 (USD Million)
8.2.7. Others : Market estimates and forecasts, 2018
to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Vendor
market share analysis, 2024
9.2. Brand
Analysis (Top Brands)
9.3. Competitive
Dashboard
9.4 Strategy Mapping
9.4.1. New
Product Launch
9.4.2.
Collaborations, Mergers & Acquisitions
9.5 Vendor Profiles
9.5.1. Merck & Co., Inc
9.5.1.1. Company overview
9.5.1.2. Financial performance
9.5.1.3. Product portfolio
9.5.1.4. Strategic initiatives
9.5.2. Bristol-Myers Squibb Company
9.5.2.1. Company overview
9.5.2.2. Financial performance
9.5.2.3. Product portfolio
9.5.2.4. Strategic initiatives
9.5.3. Genentech (ROCHE GROUP)
9.5.3.1. Company overview
9.5.3.2. Financial performance
9.5.3.3. Product portfolio
9.5.3.4. Strategic initiatives
9.5.4. AstraZeneca
9.5.4.1. Company overview
9.5.4.2. Financial performance
9.5.4.3. Product portfolio
9.5.4.4. Strategic initiatives
9.5.5. Merck KGaA
9.5.5.1. Company
overview
9.5.5.2. Financial performance
9.5.5.3. Product portfolio
9.5.5.4. Strategic initiatives
9.5.6. Regeneron Pharmaceuticals
Inc. & Sanofi
9.5.6.1. Company overview
9.5.6.2. Financial performance
9.5.6.3. Product portfolio
9.5.6.4. Strategic initiatives
9.5.7. BeiGene, Ltd.
9.5.7.1. Company overview
9.5.7.2. Financial performance
9.5.7.3. Product portfolio
9.5.7.4. Strategic initiatives
9.5.8. GSK
9.5.8.1. Company overview
9.5.8.2. Financial performance
9.5.8.3. Product portfolio
9.5.8.4. Strategic initiatives
9.5.9. Incyte Corporation
9.5.9.1. Company overview
9.5.9.2. Financial performance
9.5.9.3. Product portfolio
9.5.9.4. Strategic initiatives
9.5.10. Junshi Biosciences & Coherus
BioSciences, Inc.
9.5.10.1. Company overview
9.5.10.2. Financial performance
8.3.14.2. Product portfolio
9.5.10.4. Strategic initiatives
9.5.11. Innovent Biologics, Inc & Eli
Lilly and Company
9.5.11.1. Company overview
9.5.11.2. Financial performance
9.5.11.3. Product portfolio
9.5.11.4. Strategic initiatives
Chapter 10. Methodology and Scope
10.1. Research Methodology
10.2. Information Procurement - Sources
10.2.1. Secondary sources
10.2.2. Primary research
10.2.3. Details of primary research
10.3. Data analysis models
10.4. Market Formulation
& Validation
10.5. Questionnaire
1. Merck
& Co., Inc. – Keytruda
2. Bristol-Myers
Squibb Company – OPDIVO,YERVOY, OPDUALAG
3. Genentech
(ROCHE GROUP) – TECENTRIQ
4. AstraZeneca
- IMFINZI and IMJUDO
5. Merck KGaA – BAVENCIO
6. Regeneron Pharmaceuticals, Inc & Sanofi – LIBTAYO
7. BeiGene,
Ltd. – TEVIMBRA
8. GSK
– JEMPERLI
9. Incyte
Corporation - ZYNYZ
10. Junshi
Biosciences & Coherus BioSciences, Inc. – LOQTORZI/TUOYI
11. Innovent
Biologics, Inc & Eli Lilly and Company- Tyvyt